Compared to SERT alone, there was a significant increase in locomotor activity with SILY 140
Officially, the FDA cites: Insufficient large-scale clinical trials Concerns about consistency, sourcing, and manufacturing standards The need to meet formal drug approval requirements Critics argue (fairly) that this system: Favors large pharmaceutical companies Makes it hard to approve naturally occurring peptides Leaves promising, low-risk compounds in regulatory limbo The short version: This FDA restrictive regulatory change of mind wasnt driven by a sudden safety scare, it was driven by regulatory process and economics
We also learned about common patient experiences from medical professionals who are well-versed in the subject
Well ensure youre fully informed before your treatment
Stem cell research for Peyronies disease Stem cells for Peyronies disease is an evolving field of regenerative medicine and a promising area of research
100% Clean Formula: Free from artificial fragrances, alcohol, dyes, sulfates, parabens, heavy metals, mineral oil, and harsh chemicals